Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2006 Mar 16;35(2):175–181. doi: 10.1165/rcmb.2005-0239OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2006, American Thoracic Society

PMC Copyright notice

Figure 7. — Neutralization of CCL12, but not of CCL2, protects against FITC-induced pulmonary fibrosis. WT mice were injected with saline or FITC on Day 0. On Days 0, 7, and 14, FITC-treated mice received a 0.5-mg injection of control rat Ig, anti-CCL2, or anti-CCL12. Lungs were harvested at Day 21 after FITC, and collagen content was determined by Sircol assay. Collagen content in FITC-treated mice receiving mouse Ig as a control sera were not significantly different than the data shown for control rat Ig. Anti-CCL2 treatment reduced FITC fibrosis, but the change did not reach statistical significance, whereas anti-CCL12 treatment significantly reduced FITC-induced fibrosis compared with control Ig (n = 8, P < 0.01).